General Information of Drug (ID: DMTLR6Y)

Drug Name
3K3A-APC Drug Info
Indication
Disease Entry ICD 11 Status REF
Cerebrovascular ischaemia 8B1Z Phase 2 [1]
Ischemic stroke 8B11.5Z Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMTLR6Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sodium Tetradecyl Sulfate DM4QFXJ Hemangioma 2E81-2F2Y Approved [4]
Ancrod DMK2Y4V Blood forming organ disorder JB64.1 Phase 3 [5]
GED-aPC DM041IZ Cardiovascular disease BA00-BE2Z Discontinued in Phase 1 [6]
RPR-120844 DM1V0MD Discovery agent N.A. Investigative [7]
RPR-118071 DM61VHF Discovery agent N.A. Investigative [7]
PMID24418773C37 DMG4NQV Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vitamin K-dependent protein C (PROC) TTZUXYS PROC_HUMAN Modulator [3]

References

1 ClinicalTrials.gov (NCT02222714) Safety Evaluation of 3K3A-APC in Ischemic Stroke. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des. 2012;18(27):4215-22.
4 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
5 Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989 Dec;71(6):870-7.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2396).
7 Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem. 1999 Sep 9;42(18):3557-71.
8 Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia. Bioorg Med Chem Lett. 2014 Feb 1;24(3):821-7.